The price of Sovaldi and its impact on the U.S. health care system / 
prepared by the staffs of ranking member Ron Wyden and committee member Charles E. Grassley, Committee on Finance, United States Senate. 
 - 2 volumes (viii, 1980 pages) :  illustrations ;  24 cm. 
 - S. prt. ;  114-20 .
 - S. prt. ;  114-20. .
<br/><br/> At head of title: 114th Congress, 1st session. Committee print.  Shipping list no.: 2016-0082-M.  "December 2015."  CRDP Project record. 
<br/><br/>Includes bibliographical references. 
<br/><br/><br/>Microfiche. <br/>[Washington, D.C.] : <br/>U.S. Government Printing Office, <br/>[2016] <br/>34 microfiches : negative. 
<br/><br/><label>Subjects--Corporate Names: </label><br/>Gilead Sciences (Firm)
<br/><br/><label>Subjects--Topical Terms: </label><br/>Sofosbuvir--Prices--United States.<br/>Hepatitis C--Chemotherapy--Costs.--United States<br/>Sulfonamides--Prices--United States.<br/>Antiviral agents--Prices--United States.
<br/><br/><label>Index Terms--Genre/Form: </label><br/>Legislative materials.
<br/><br/><label>LC Class. No.: </label>KF31  / .F5 2015 
<br/><br/><label>GPO Item No.: </label>1038-B (MF) 
<br/><br/><label>Gov. Doc. Class. No.: </label>Y 4.F 49:S.PRT.114-20/